Metastatic Recurrence

Disease

Related News

ctDNA and urine DNA testing may help select bladder-sparing treatment in muscle-invasive bladder cancer

Apr 15, 2026

Studies in muscle-invasive bladder cancer found ctDNA predicted metastatic risk after bladder-sparing treatment, while urine tumor DNA was more sensitive for residual bladder disease. Data from RETAIN-2 and a PNAS study support molecular testing to help select patients for bladder preservation.

Enfortumab Vedotin Plus Pembrolizumab Improves Survival in Muscle-Invasive Bladder Cancer

Mar 05, 2026

Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.

New Molecular Testing May Help Bladder Cancer Patients Avoid Surgery

Feb 25, 2026

Ultrasensitive testing of tumor DNA in blood and urine may identify muscle-invasive bladder cancer patients who can safely forgo radical cystectomy, with 69% achieving 3-year bladder-intact survival after systemic therapy.